Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYingbo ShaoYHYaning HeFGFangfang Guo

Discussion

Loading...

Member takes

Overview

Real-world analysis reveals germline BRCA mutation affects clinical outcomes in metastatic breast cancer treated with CDK4/6 inhibitors, suggesting implications for treatment strategies.

Key Points

  • Germline BRCA mutation may negatively influence clinical outcomes in metastatic breast cancer treated with CDK4/6 inhibitors.
  • Patients with gBRCA mutation had a median progression free survival of 9.2 months, compared to 18.5 months for gBRCA wt patients.
  • The objective response rate was 0% for gBRCA mutation patients, versus 35% for gBRCA wt, highlighting an efficacy difference.
  • Disease control rate for gBRCA mutation patients was 33.3%, significantly lower than 75% for gBRCA wt patients, indicating a treatment disparity.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf63dhttps://doi.org/10.21203/rs.3.rs-7072445/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of <i>BRCA</i> Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis2025
  2. 2Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status2025
  3. 3Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis2025
  4. 4Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancer2025
  5. 5Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety2025